Aerovate Therapeutics Inc
NASDAQ:AVTE

Watchlist Manager
Aerovate Therapeutics Inc Logo
Aerovate Therapeutics Inc
NASDAQ:AVTE
Watchlist
Price: 2.53 USD Market Closed
Market Cap: 73m USD
Have any thoughts about
Aerovate Therapeutics Inc?
Write Note

Aerovate Therapeutics Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Aerovate Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Aerovate Therapeutics Inc
NASDAQ:AVTE
Operating Income
-$81.4m
CAGR 3-Years
-109%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$15.4B
CAGR 3-Years
-5%
CAGR 5-Years
3%
CAGR 10-Years
10%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$10.9B
CAGR 3-Years
-3%
CAGR 5-Years
20%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Operating Income
$6.2B
CAGR 3-Years
-11%
CAGR 5-Years
-9%
CAGR 10-Years
-1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.3B
CAGR 3-Years
17%
CAGR 5-Years
40%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$4.2B
CAGR 3-Years
-18%
CAGR 5-Years
13%
CAGR 10-Years
18%
No Stocks Found

Aerovate Therapeutics Inc
Glance View

Market Cap
73m USD
Industry
Biotechnology

Aerovate Therapeutics, Inc. is a biotechnology company which engages in the development of drugs for rare cardiopulmonary disease. The company is headquartered in Boston, Massachusetts and currently employs 16 full-time employees. The company went IPO on 2021-06-30. The firm is focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The firm's lead program is a drug that addresses the core disease processes of pulmonary arterial hypertension (PAH). AV-101 is an inhaled dry powder formulation of imatinib that conveniently delivers the medicine directly to the diseased lung tissues while reducing systemic adverse effects. AV-101's anti-proliferative mechanism is distinguished from vasodilatory therapies and is poised to make a meaningful difference in the lives of PAH patients. The firm has completed a Phase I trial in the United States of AV-101 in 82 healthy adults. In its Phase I trial, there were no adverse events associated with AV-101. The company anticipates initiating a double-blinded, placebo-controlled, randomized Phase II b/III trial of AV-101.

AVTE Intrinsic Value
4.24 USD
Undervaluation 40%
Intrinsic Value
Price

See Also

What is Aerovate Therapeutics Inc's Operating Income?
Operating Income
-81.4m USD

Based on the financial report for Dec 31, 2023, Aerovate Therapeutics Inc's Operating Income amounts to -81.4m USD.

What is Aerovate Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-109%

Over the last year, the Operating Income growth was -53%. The average annual Operating Income growth rates for Aerovate Therapeutics Inc have been -109% over the past three years .

Back to Top